News

European Leadership Changes and Appointment of VP Sales and Marketing, EMEA

Melbourne (Australia) – 21st February 2020. Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her position of Telix EU President.

Telix Pharmaceuticals Limited has announced that Ms Odile Jaume will be stepping down from her position of Telix EU President. Ms Jaume will continue in an advisory capacity to Telix as it completes the acquisition and regulatory approvals for its Belgian radiopharmaceutical manufacturing facility (Seneffe, Belgium).

Mr Ludo Wouters, Vice President of Corporate Development for Telix Europe (and Managing Director of ANMI SA, a wholly owned subsidiary of Telix) will serve as Interim President of Telix’s European operations while the Company undertakes a comprehensive search and evaluation for a replacement executive appointment, including review of internal candidates.

Telix is also pleased to announce the appointment of Mr Christian Davis to the position of Vice President Sales and Marketing, EMEA.

To read the full media release click here.

More Articles

ASX Announcements

Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic

Indianapolis IN and Columbus OH (U.S.A) – 8 April 2020. Telix Pharmaceuticals (U.S.) Inc. is pleased to announce it has...

News

Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC

Melbourne (Australia) – 16 Mar 2020. Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance...

News

Business Update : COVID-19

Melbourne (Australia) – 13 Mar 2020. Telix provides an update on the Company’s risk management assessment of the novel coronavirus...

News

Leader in prostate cancer imaging Prof. Frederik L. Giesel joins Scientific Advisory Board

Melbourne (Australia) – 9 March 2020. Telix Pharmaceuticals Limited announces that Professor Dr. Frederik L. Giesel, MD, MBA has joined...

News

Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)

Melbourne (Australia) – 25 Feb 2020. Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its...

News

Telix Pharmaceuticals Releases Annual Report Year Ending 2019

Melbourne (Australia) - 24 Feb 2020. Telix Pharmaceuticals Limited is pleased to provide its Annual Report for the year ending...

News

European Leadership Changes and Appointment of VP Sales and Marketing, EMEA

Melbourne (Australia) – 21st February 2020. Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her...

ASX Release

Telix completes acquisition of European radiopharmaceutical production facility

Melbourne (Australia) – 3 April 2020. Telix is pleased to announce it has now completed the acquisition of a licensed...